| Schedule of consolidated net loss summarized by the significant segment expenses regularly reviewed by the CODM |
The following table presents consolidated net loss summarized by the significant segment expenses regularly reviewed by the CODM for the three and six months ended December 31, 2025, and 2024 (in thousands): | | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | December 31, | | December 31, | | 2025 | | 2024 | | 2025 | | 2024 | Research and development: | | | | | | | | | | | | Ersodetug | $ | 5,647 | | $ | 7,260 | | $ | 11,257 | | $ | 14,476 | Compensation and benefits | | 6,991 | | | 4,491 | | | 12,579 | | | 8,788 | Other research and development segment expenses (1) | | 1,710 | | | 876 | | | 3,661 | | | 2,117 | Total research and development | | 14,348 | | | 12,627 | | | 27,497 | | | 25,381 | General and administrative: | | | | | | | | | | | | Compensation and benefits | | 4,917 | | | 2,602 | | | 8,267 | | | 4,854 | Other general and administrative segment expenses (2) | | 4,956 | | | 1,851 | | | 8,274 | | | 3,786 | Total general and administrative | | 9,873 | | | 4,453 | | | 16,541 | | | 8,640 | Operating loss | | (24,221) | | | (17,080) | | | (44,038) | | | (34,021) | Total non-operating income, net | | 1,447 | | | 1,350 | | | 3,114 | | | 2,913 | Net loss | $ | (22,774) | | $ | (15,730) | | $ | (40,924) | | $ | (31,108) |
| (1) | Other research and development segment expenses primarily include quality regulatory and other pipeline development costs, employee travel and expense, and other facility and information technology costs. |
| (2) | Other general and administrative segment expenses primarily include consulting expenses related to business development and market planning activities, insurance expense, public company costs, employee travel and expense, and other facility and information technology costs. |
|